Theravance Biopharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Theravance Biopharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.52M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $4.28M | Feb 28, 2018 |
| FY2017 | Jun 30, 2017 | $3.51M | Feb 28, 2018 |
| FY2017 | Mar 31, 2017 | $3.09M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $5.69M | Feb 28, 2018 |
| FY2017 | Sep 30, 2016 | $19.08M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $5.47M | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $18.41M | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $3.89M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $10.70M | Mar 1, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.89M | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | $19.99M | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | $26.20M | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | $15.39M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $18.75M | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | $16.87M | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | $14.26M | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | $14.50M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $17.57M | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | $15.69M | Mar 7, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.02M | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | $3.62M | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | $54.84M | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | ($13.58M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($15.53M) | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | ($12.70M) | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | ($16.53M) | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | ($11.66M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($8.51M) | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | ($8.95M) | Mar 7, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.01M | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | ($6.46M) | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | ($2.73M) | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | ($14.43M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($9.20M) | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | ($10.84M) | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | ($15.71M) | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | ($11.21M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($6.24M) | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | ($8.76M) | Mar 7, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.41M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $37.64M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $40.62M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $63.39M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $193.66M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $260.95M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $219.25M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $201.35M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $173.89M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $141.71M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.65M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $69.17M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $70.10M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $67.07M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $99.30M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $108.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $106.08M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $97.06M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $95.59M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $84.51M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.54M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($11.54M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($27.00M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($186.99M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($207.86M) | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | ($250.40M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($238.20M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($112.87M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($201.05M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | ($98.99M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $2.14M | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $2.65M | Mar 1, 2017 |
| FY2016 | Dec 31, 2014 | $3.11M | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $2.73M | Mar 11, 2016 |
| FY2014 | Dec 31, 2012 | $2.59M | Mar 13, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $485.57M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $354.16M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $382.00M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $607.40M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $374.82M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $469.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $408.83M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $560.24M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $441.40M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $639.25M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $296.72M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $175.55M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $213.00M | Mar 7, 2025 |
| FY2024 | Dec 31, 2022 | $441.80M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | ($338.57M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($303.75M) | Mar 1, 2023 |
| FY2022 | Dec 31, 2019 | ($223.84M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | ($51.59M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $115.18M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $350.23M | Feb 27, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($859.63M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($965.52M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($909.10M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($853.91M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.73B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($1.53B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.25B) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($1.01B) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($797.74M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($512.23M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.81M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $37.80M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $39.55M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $298.17M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $89.96M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $81.47M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $58.06M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $378.02M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $88.98M | Feb 27, 2020 |
| FY2017 | Dec 31, 2016 | $344.71M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $616.33M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $619.17M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $455.04M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $454.35M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $223.75M | Feb 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 7, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2025 | 1 | Mar 23, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Mar 23, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 7, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.07M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 49.47M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 48.09M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 65.23M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 74.44M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 64.33M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 57.02M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 55.68M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 54.38M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 52.83M | Feb 28, 2018 |